Neogenomics Inc (NASDAQ: NEO) has reported E.P.S. of $-0.12 for its fourth fiscal quarter (ending December 31) versus $-0.11 for the same period a year ago — an increase of 9%. For the latest four quarters through December 31, E.P.S. were $-0.62 versus $-0.70 for the same period a year ago — a decline of -11%.
Recent Price Action
Neogenomics Inc (NASDAQ: NEO) stock suffered a major decline of -14.0% on 2/18/25. The shares closed at $12.40. Moreover, this decline was accompanied by exceptionally high trading volume at 456% of normal. The stock has been strong relative to the market over the last nine months but has declined -7.8% during the last week.
Current PriceTarget Research Rating
Neogenomics has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Neogenomics has a poor Appreciation Score of 28 but a neutral Power Rating of 60, leading to the Negative Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment